Effects of pitavastatin on pressure overload-induced heart failure in mice

Circulation Journal

Volumn 76, Issue 5, 2012, Pages 1159-1168

  Kameda, Yoshihito ^a   Hasegawa, Hiroshi ^a   Kubota, Akihiko ^a   Tadokoro, Hiroyuki ^c   Kobayashi, Yoshio ^a   Komuro, Issei ^d   Takano, Hiroyuki ^b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Cardiac fibrosis; Heart failure; HMG CoA reductase inhibitor; Left ventricular hypertrophy

Indexed keywords

ANGIOPOIETIN 1; ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 6; FIBRONECTIN; PITAVASTATIN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEART VENTRICLE SIZE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; M MODE ECHOCARDIOGRAPHY; MOUSE; NONHUMAN; OXIDATIVE STRESS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANGIOPOIETIN-1; ANIMALS; BLOOD PRESSURE; FIBROSIS; GENE EXPRESSION REGULATION; HEART FAILURE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTROPHY, LEFT VENTRICULAR; MICE; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; QUINOLINES; TIME FACTORS;

EID: 84860153301     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1114     Document Type: Article

References (45)

1. Frey N, Olson EN. Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79.
2. Frohlich ED. Cardiac hypertrophy in hypertension. N Engl J Med 1987; 317: 831-833.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
4. Tavi P, Laine M, Weckstrom M, Ruskoaho H. Cardiac mechanotransduction: From sensing to disease and treatment. Trends Pharmacol Sci 2001; 22: 254-260.
5. Katz AM. The cardiomyopathy of overload: An unnatural growth response in the hypertrophied heart. Ann Intern Med 1994; 121: 363-371.
6. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
7. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
9. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
10. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1-10.
11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
12. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
13. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: Evidence for antiinflammatory effects of rosuvastatin. Circulation 2003; 108: 1368-1374.
14. Izumi Y, Shiota M, Kusakabe H, Hikita Y, Nakao T, Nakamura Y, et al. Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. Hypertens Res 2009; 32: 675-679.
15. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
16. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and Rho proteins. Circ Res 1998; 83: 683-690.
17. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105: 868-873.
18. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108: 1429-1437.
19. Hasegawa H, Yamamoto R, Takano H, Mizukami M, Asakawa M, Nagai T, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003; 35: 953-960.
20. Maejima Y, Nobori K, Ono Y, Adachi S, Suzuki J, Hirao K, et al. Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: The HF-COSTAR trial. Circ J 2011; 75: 589-595.
21. Tsutamoto T, Sakai H, Ibe K, Yamaji M, Kawahara C, Nakae I, et al. Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Circ J 2011; 75: 2160-2166.
22. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci USA 1991; 88: 8277-8281.
23. Beckles DL, Mascareno E, Siddiqui MA. Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vascul Pharmacol 2006; 45: 350-357.
24. Mohammed SF, Storlie JR, Oehler EA, Bowen LA, Korinek J, Lam CS, et al. Variable phenotype in murine transverse aortic constriction. Cardiovasc Pathol 2011 (in press).
25. Tarnavski O. Mouse surgical models in cardiovascular research. Methods Mol Biol 2009; 573: 115-137.
26. Xia Y, Lee K, Li N, Corbett D, Mendoza L, Frangogiannis NG. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem Cell Biol 2009; 131: 471-481.
27. Zhao H, Liao Y, Minamino T, Asano Y, Asakura M, Kim J, et al. Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress. Hypertens Res 2008; 31: 1977-1987.
28. Ueda K, Takano H, Niitsuma Y, Hasegawa H, Uchiyama R, Oka T, et al. Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest 2010; 120: 2016-2029.
29. Hasegawa H, Takano H, Kohro T, Ueda K, Niitsuma Y, Aburatani H, et al. Amelioration of hypertensive heart failure by amlodipine may occur via antioxidative effects. Hypertens Res 2006; 29: 719-729.
30. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
31. Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 2006; 113: 1588-1596.
32. Nagano M, Higaki J, Mikami H, Nakamaru M, Higashimori K, Katahira K, et al. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens 1991; 9: 595-599.
33. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 2002; 40: 142-147.
34. Flores NA. Pitavastatin Nissan/Kowa Yakuhin/Novartis/Sankyo. Curr Opin Investig Drugs 2002; 3: 1334-1341.
35. Saito Y, Yamada N, Teramoto T, Itakura H, Hata Y, Nakaya N, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002; 162: 373-379.
36. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998; 83: 233-240.
37. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 282: 468-471.
38. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000; 275: 9102-9105.
39. Harfouche R, Hassessian HM, Guo Y, Faivre V, Srikant CB, Yancopoulos GD, et al. Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 2002; 64: 135-147.
40. Peters KG, Kontos CD, Lin PC, Wong AL, Rao P, Huang L, et al. Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res 2004; 59: 51-71.
41. Fukuhara S, Sako K, Noda K, Zhang J, Minami M, Mochizuki N. Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis. Histol Histopathol 2010; 25: 387-396.
42. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Noda A, et al. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: Potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway. Clin Exp Pharmacol Physiol 2006; 33: 1164-1171.
43. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
44. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-1239.
45. Bezerra DG, Mandarim-de-Lacerda CA. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats. Clin Sci (Lond) 2005; 108: 349-355.